Green Thumb Industries (GTBIF) was counting on federal marijuana rescheduling to deliver meaningful financial relief, but a fresh regulatory dispute is threatening to push the timeline further out.
The latest obstacle stems from a Government Accountability Office report examining how federal agencies evaluate controlled substances, which opponents of rescheduling want added to the administrative record.
Those opponents are also seeking additional testimony and access to documents, moves that could significantly slow the process of moving marijuana from Schedule I to Schedule III.
The DEA has indicated it does not object to including the GAO report, but the supplementary requests introduce new complications that have frustrated cannabis industry stakeholders already waiting years for reform.
For Green Thumb specifically, rescheduling matters because it could eliminate a major federal tax burden currently preventing the company from retaining a larger share of its earnings.
Under existing law, cannabis companies operating in federally illegal categories face significant tax restrictions that most other American businesses simply do not encounter.
Despite that ongoing disadvantage, Green Thumb generated $29 million in operating cash flow during the second quarter of 2026, demonstrating the underlying strength of its business model.
Revenue reached $306.7 million during the same period, while normalized EBITDA totaled $84.3 million and the company reported $4.9 million in net income.
Those figures suggest Green Thumb is capable of sustaining meaningful financial performance even without any resolution to the rescheduling debate in Washington.
At approximately $6.40 per share, Green Thumb carries a market capitalization of around $1.4 billion, representing roughly 1.1 times annualized second-quarter revenue.
That valuation is considered relatively modest given the company’s established retail network, positive earnings, and consistent cash generation across recent quarters.
The stock’s current price level also leaves room for upside if Green Thumb can continue stabilizing its margins independent of federal policy changes.
Investors betting on cannabis stocks purely for rescheduling catalysts have faced repeated disappointment, making Green Thumb’s operational track record a more reliable foundation for an investment thesis.
If rescheduling does eventually clear all regulatory hurdles, the elimination of that federal tax restriction could represent a significant additional boost to Green Thumb’s bottom line.
Until that day arrives, the company’s financials suggest it is well-positioned to keep generating cash and absorbing the ongoing costs of an uncertain regulatory environment.
